Nafld and Nash: Biomarkers in Detection, Diagnosis and Monitoring

ISBN-13: 9783030371753 / Angielski / Miękka / 2021 / 236 str.

Manuel Romero-Gomez

Spis treści

Foreword.- Biochemical biomarkers of NAFLD/NASH.- MR based-Imaging Biomarkers in NAFLD/NASH.- Detection of NAFLD/NASH in general population.- Micro-vesicles in the diagnosis and monitoring of NASH.- Non-invasive biomarkers for monitoring NASH: NASH resolution and Fibrosis regression.- From transcriptome to proteomic in the development of biomarkers in NAFLD/NASH.- Transient elastography and ultrasound as imaging biomarkers in NAFLD/NASH.- Early detection of HCC in patients with NAFLD/NASH.- Genes and NAFLD/NASH progression.- Geometry of nutrition: micronutrients and NAFLD progression.- Psychological biomarkers profile in NAFLD/NASH with advanced fibrosis.- Integrative proposal of biomarkers use in clinical practice management of NAFLD/NASH.

O autorze

MANUEL ROMERO GÓMEZ Is Full-Professor of Medicine in the University of Seville, Spain. Digestive Diseases Department at Virgen del Rocío University Hospitals. Institute of Biomedicine of Seville (IBIS). University of Seville. Spain.

Coordinator of the Spanish Registry of NAFLD/NASH (HepaMET) and co-coordinator of the EASL supported European Registry of NAFLD. Principal Investigator of the group for research in the Spanish Network for Research in Digestive and liver diseases (CiberEHD).

 Prof Romero-Gómez received the XI Award Javier Benjumea Puigcerver in investigation, Universidad de Sevilla-Focus Abengoa, 2014. He was awarded with the Medal of The City of Seville in 2016. He has published more than 300 peer-reviewed papers on gastrointestinal and liver diseases. He has protected 10 patents and participated as PI in more than 20 competitive grants for research.

Blurb

This book provides a comprehensive overview of the diagnosis and management of Non-alcoholic Fatty Liver Disease (NAFLD) and Non-Alcoholic Steatohepatis (NASH). Basic principles of disease progression, the genetic and nutritional basis of NAFLD and NASH are explained along with the proteomic principles underlying biomarker development. Chapters cover both biochemical and imaging biomarkers used in elastrography and ultrasound and discuss how these are applicable to early diagnosis and monitoring of NASH and NAFLD.  

This is a useful resource for hepatologists, primary care providers with an interest in metabolic disease, diabetologists and endocrinologists in their daily clinical practice.